JP2005515981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515981A5 JP2005515981A5 JP2003545329A JP2003545329A JP2005515981A5 JP 2005515981 A5 JP2005515981 A5 JP 2005515981A5 JP 2003545329 A JP2003545329 A JP 2003545329A JP 2003545329 A JP2003545329 A JP 2003545329A JP 2005515981 A5 JP2005515981 A5 JP 2005515981A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- terminus
- seq
- fcγr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000009465 prokaryotic expression Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10157290.5 | 2001-11-22 | ||
| DE10157290A DE10157290A1 (de) | 2001-11-22 | 2001-11-22 | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
| PCT/EP2002/013080 WO2003043648A2 (de) | 2001-11-22 | 2002-11-21 | Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005515981A JP2005515981A (ja) | 2005-06-02 |
| JP2005515981A5 true JP2005515981A5 (https=) | 2006-01-19 |
| JP5414959B2 JP5414959B2 (ja) | 2014-02-12 |
Family
ID=7706571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545329A Expired - Lifetime JP5414959B2 (ja) | 2001-11-22 | 2002-11-21 | ｓＦｃγＲＩＩｂまたはｓＦｃγＲＩＩＩを含有する医薬品組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20050002924A1 (https=) |
| EP (1) | EP1446139B1 (https=) |
| JP (1) | JP5414959B2 (https=) |
| AT (1) | ATE409045T1 (https=) |
| AU (1) | AU2002366200A1 (https=) |
| CA (1) | CA2506068C (https=) |
| CO (1) | CO5590936A2 (https=) |
| DE (2) | DE10157290A1 (https=) |
| ES (1) | ES2309238T3 (https=) |
| WO (1) | WO2003043648A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004293184B2 (en) * | 2003-11-26 | 2010-12-16 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Substance binding human IgG Fc receptor IIb |
| US10028998B2 (en) * | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
| US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
| WO2014067959A1 (en) | 2012-10-30 | 2014-05-08 | Suppremol Gmbh | A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease |
| AU2012244302B2 (en) * | 2012-10-31 | 2014-08-21 | Suppremol Gmbh | A method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease |
| EP2796144A1 (en) * | 2013-04-26 | 2014-10-29 | SuppreMol GmbH | Highly concentrated Formulations of soluble Fc receptors |
| EP2833139A1 (en) * | 2013-08-01 | 2015-02-04 | SuppreMol GmbH | In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN105873600B (zh) * | 2013-10-16 | 2019-11-05 | 苏伯利莫尔公司 | 用于自身免疫性大疱病治疗的可溶性Fcγ受体 |
| JP6893223B2 (ja) * | 2013-10-16 | 2021-06-23 | ズプレモル ゲーエムベーハー | 医薬品組成物およびキット |
| JP2018050616A (ja) | 2016-09-23 | 2018-04-05 | 東ソー株式会社 | 改良型組換えＦｃγＲＩＩ |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291198A (zh) * | 1998-02-06 | 2001-04-11 | 伊来克萨斯独资有限公司 | Fc受体的三维结构和模型及其应用 |
| EP1006183A1 (en) * | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| EP1201681A1 (en) * | 2000-10-30 | 2002-05-02 | Millennium Pharmaceuticals, Inc. | "Fail" molecules and uses thereof |
-
2001
- 2001-11-22 DE DE10157290A patent/DE10157290A1/de not_active Withdrawn
-
2002
- 2002-11-21 AT AT02803402T patent/ATE409045T1/de active
- 2002-11-21 CA CA2506068A patent/CA2506068C/en not_active Expired - Lifetime
- 2002-11-21 DE DE50212814T patent/DE50212814D1/de not_active Expired - Lifetime
- 2002-11-21 WO PCT/EP2002/013080 patent/WO2003043648A2/de not_active Ceased
- 2002-11-21 JP JP2003545329A patent/JP5414959B2/ja not_active Expired - Lifetime
- 2002-11-21 EP EP02803402A patent/EP1446139B1/de not_active Expired - Lifetime
- 2002-11-21 AU AU2002366200A patent/AU2002366200A1/en not_active Abandoned
- 2002-11-21 ES ES02803402T patent/ES2309238T3/es not_active Expired - Lifetime
-
2004
- 2004-05-24 US US10/851,655 patent/US20050002924A1/en not_active Abandoned
- 2004-06-18 CO CO04057552A patent/CO5590936A2/es not_active Application Discontinuation
-
2008
- 2008-01-09 US US11/971,438 patent/US20080214459A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chorev | The partial retro–inverso modification: A road traveled together | |
| TWI250988B (en) | Thrombopoietic compounds | |
| RU2214267C2 (ru) | Пептидный антагонист зонулина | |
| Zdanov | Structural features of the interleukin-10 family of cytokines | |
| Chang et al. | Analgesic activity of intracerebroventricular administration of morphiceptin and β-casomorphins: correlation with the morphine (μ) receptor binding affinity | |
| Efimov | A novel super-secondary structure of proteins and the relation between the structure and the amino acid sequence | |
| JP2005515981A5 (https=) | ||
| JPH06504192A (ja) | ポリペプチドおよびその使用 | |
| WO2001083527A3 (en) | Glucagon antagonists | |
| KR960700739A (ko) | Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses) | |
| JP2010534486A5 (https=) | ||
| KR920019820A (ko) | 히브리드 폴리펩티드 조성물, 히브리드 폴리펩티드의 제조방법 및 이를위한 dna 발현벡터 | |
| JP2017527272A5 (https=) | ||
| RU2014122609A (ru) | Модифицированная константная область антитела | |
| CA2230160A1 (en) | Antimicrobial cationic peptides and methods of screening for the same | |
| NO327080B1 (no) | Syntetisk opioidpeptidamid samt et farmasoytisk preparat | |
| CA2579798A1 (en) | Interleukin-15 antagonist peptide | |
| JP2002514418A5 (https=) | ||
| WO1999060013A3 (en) | Il-6 antagonist peptides | |
| PL363071A1 (pl) | Sposoby i kompozycje dla zmniejszenia replikacji HIV-1 | |
| CA2155103A1 (en) | Tnf-alpha muteins and a process for preparing them | |
| IL106271A (en) | Ligand to TNF 75P receptor and its preparation | |
| CN106232810A (zh) | 新的治疗 | |
| CA2506068A1 (en) | Pharmaceutical composition containing sfcyr iib or sfcyr iii | |
| JP2004505640A5 (https=) |